LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

Search

Bristol-Myers Squibb Co.

Open

SectorGezondheidszorg

46.83 0.17

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

46.37

Max

47.06

Belangrijke statistieken

By Trading Economics

Inkomsten

2.4B

2.5B

Verkoop

-1.1B

11B

K/W

Sectorgemiddelde

17.384

56.602

EPS

1.8

Dividendrendement

5.15

Winstmarge

21.98

Werknemers

34,100

EBITDA

1.9B

4.5B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+20.32% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

5.15%

2.45%

Volgende Winsten

31 jul 2025

Volgende dividenddatum

31 jul 2025

Volgende Ex Dividend datum

4 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-17B

95B

Vorige openingsprijs

46.66

Vorige sluitingsprijs

46.83

Nieuwssentiment

By Acuity

31%

69%

76 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Bristol-Myers Squibb Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2025, 11:32 UTC

Winsten

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

13 mei 2025, 16:48 UTC

Acquisities, Fusies, Overnames

2seventy bio: Bristol Myers Squibb Completes Acquisition of 2seventy

12 mei 2025, 22:14 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mei 2025, 18:45 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mei 2025, 17:14 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12 mei 2025, 12:07 UTC

Marktinformatie

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

7 mei 2025, 20:09 UTC

Winsten
Acquisities, Fusies, Overnames

2seventy Bio 1Q Rev $22.9M >TSVT

7 mei 2025, 20:08 UTC

Winsten
Acquisities, Fusies, Overnames

2seventy Bio 1Q EPS 1c >TSVT

7 mei 2025, 20:08 UTC

Winsten
Acquisities, Fusies, Overnames

2seventy Bio: Tender Offer Related to Bristol Myers Squibb Deal to Expire May 12 Unless Extended

7 mei 2025, 20:07 UTC

Winsten
Acquisities, Fusies, Overnames

2seventy Bio: HSR Waiting Period Expired for Sale to Bristol Myers Squibb

29 apr 2025, 19:47 UTC

Winsten

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29 apr 2025, 15:22 UTC

Winsten

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29 apr 2025, 11:46 UTC

Winsten

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29 apr 2025, 11:42 UTC

Winsten

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29 apr 2025, 11:12 UTC

Winsten

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

28 apr 2025, 21:15 UTC

Winsten

Pfizer Reports Earnings as Stock Sits in Doldrums -- Barrons.com

24 apr 2025, 21:24 UTC

Top Nieuws
Winsten

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr 2025, 14:15 UTC

Top Nieuws
Winsten

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr 2025, 12:37 UTC

Marktinformatie
Winsten

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

24 apr 2025, 11:17 UTC

Winsten

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

24 apr 2025, 11:13 UTC

Top Nieuws
Winsten

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

Peer Vergelijking

Prijswijziging

Bristol-Myers Squibb Co. Prognose

Koersdoel

By TipRanks

20.32% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 56.25 USD  20.32%

Hoogste 68 USD

Laagste 36 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bristol-Myers Squibb Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

20 ratings

5

Buy

14

Hold

1

Sell

Technische score

By Trading Central

N/A / 50.57Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

76 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.